Results 91 to 100 of about 221,455 (333)

Upper Cervical Cord Area as a Biomarker of Conversion to Secondary Progressive Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective This study assessed whether upper cervical cord area (UCCA) measured on routine brain MRI can serve as a biomarker of conversion to SPMS. Methods This is a single‐center retrospective cohort study of RRMS patients with cross‐sectional and longitudinal analyses of clinical and MRI data. Future SPMS converters were matched by age, sex,
Nabil K. El Ayoubi, Sola Al Ghazal, Salem Hannoun, Medhat A. Siddik, Nour M. Najjar, Jim Dagher, Joseph Abboud, Myriam G. Semaan, Samia J. Khoury   +8 more
wiley   +1 more source

Risk Factors for Persistent Hypogammaglobulinemia in Pediatric and Young Adult Patients Receiving Rituximab

Journal of Human Immunity
RationaleRituximab is an anti-CD20 monoclonal antibody that can cause persistent hypogammaglobulinemia (PH) in 20–45% of patients, depending on the patient population. Risk factors for PH in pediatric patients following rituximab have been inconsistently
Kevin Ackerman, Nathaniel Srikureja, Jennifer Heimall, Di Sun   +3 more
doaj   +1 more source

The impact of Rituximab administered before transplantation in patients undergoing allogeneic hematopoietic stem cell transplantation: A real-world study

Frontiers in Immunology, 2022
Rituximab is used to eliminate B cells as a chimeric monoclonal antibody directed against CD20, a B-cell antigen expressed on B cells. To explore the impact of rituximab administered before transplantation, we implemented a retrospective, monocentric ...
Xiya Wei, Xiya Wei, Yiyu Xie, Yiyu Xie, Ruoyu Jiang, Ruoyu Jiang, Huiyu Li, Huiyu Li, Heqing Wu, Heqing Wu, Yuqi Zhang, Yuqi Zhang, Ling Li, Ling Li, Shiyuan Zhou, Shiyuan Zhou, Xiao Ma, Xiao Ma, Zaixiang Tang, Jun He, Jun He, Depei Wu, Depei Wu, Xiaojin Wu, Xiaojin Wu   +24 more
doaj   +1 more source

Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience

Advances in Therapy, 2017
Rituximab is a human/murine, chimeric anti-CD20 monoclonal antibody with established efficacy, and a favorable and well-defined safety profile in patients with various CD20-expressing lymphoid malignancies, including indolent and aggressive forms of B ...
G. Salles, M. Barrett, R. Foà, J. Maurer, S. O'Brien, N. Valente, M. Wenger, D. Maloney   +7 more
semanticscholar   +1 more source

Quantitative MRI Uncovers Subtle Cortical Damage in Myelin Oligodendrocyte Glycoprotein Antibody‐Associated Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To determine whether myelin‐sensitive quantitative MRI reveals microstructural abnormalities in normal‐appearing cortex (NACtx) in myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), indicating that conventional MRI underestimates remission residual cortical injury.
Valentina Camera, Agnese Tamanti, Silvia Messina, Nicola Dall'Osto, Teresa Maltempo, Stefano Ziccardi, Matteo Foschi, Maria Grazia Piscaglia, Diana Ferraro, Francesco Crescenzo, Francesca Rossi, Albulena Bajrami, Sabrina Marangoni, Damiano Marastoni, Francesca Benedetta Pizzini, Maria Isabel Leite, Roberta Magliozzi, Patrick Waters, Massimiliano Calabrese, Jacqueline Palace, Ruth Geraldes   +20 more
wiley   +1 more source

The synergistic interaction between CD20 monoclonal antibodies and Histone Deacetylase inhibitors in B cell Non Hodgkin’s Lymphoma

, 2010
Recent improvements in molecular sub typing of Non Hodgkin’s lymphomashave resulted in targeted therapies becoming incorporated into treatmentparadigms.
Nolan, David Francis Luke
core   +1 more source

Obinutuzumab and Ofatumumab are More Effective Than Rituximab in the Treatment of Membranous Nephropathy Patients With Anti-Rituximab Antibodies

Kidney International Reports
Introduction: Although rituximab has significantly improved outcomes for patients with membranous nephropathy, response to treatment is not universal and drug resistance can occur.
Maxime Teisseyre, Marco Allinovi, Vincent Audard, Marion Cremoni, Giulia Belvederi, Alexandre Karamé, Matteo Accinno, Julien Duquesne, Vinod Sharma, Céline Fernandez, Kévin Zorzi, Mounir El Maï, Vesna Brglez, Sylvia Benzaken, Vincent L.M. Esnault, Alessandra Vultaggio, Harbir Singh Kohli, Raja Ramachandran, Calogero Lino Cirami, Barbara Seitz-Polski   +19 more
doaj   +1 more source

Rituximab in Minimal Change Disease

Canadian Journal of Kidney Health and Disease, 2017
Treatment with rituximab, a monoclonal antibody against the B-lymphocyte surface protein CD20, leads to the depletion of B cells. Recently, rituximab was reported to effectively prevent relapses of glucocorticoid-dependent or frequently relapsing minimal
Nima Madanchi, Martin Bitzan, Tomoko Takano   +2 more
doaj   +1 more source

AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma

Journal of Clinical Oncology, 2019
PURPOSE Patients with indolent non-Hodgkin lymphoma typically respond well to first-line immunochemotherapy. At relapse, single-agent rituximab is commonly administered.
J. Leonard, M. Trněný, K. Izutsu, N. Fowler, X. Hong, Jun Zhu, Hui-Lai Zhang, F. Offner, A. Scheliga, G. Nowakowski, A. Pinto, F. Re, L. Fogliatto, P. Scheinberg, I. Flinn, C. Moreira, J. Cabeçadas, David R. Liu, S. Kalambakas, P. Fustier, Cheng-Qing Wu, J. Gribben   +21 more
semanticscholar   +1 more source

Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis

Arthritis & Rheumatology, 2020
To assess the safety, mechanism of action, and preliminary efficacy of rituximab followed by belimumab in the treatment of refractory lupus nephritis (LN).
Y. Atisha-Fregoso, S. Malkiel, Kristina M. Harris, M. Byron, Lin-Na Ding, S. Kanaparthi, William T. Barry, Wendy Gao, Kristin Ryker, Patti Tosta, A. Askanase, S. Boackle, W. Chatham, D. Kamen, D. Karp, K. Kirou, S. S. Lim, B. Marder, M. McMahon, Samir V. Parikh, William F. Pendergraft, Amber S. Podoll, A. Saxena, D. Wofsy, B. Diamond, D. Smilek, C. Aranow, M. Dall'Era   +27 more
semanticscholar   +1 more source